Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor‐1α gene mutations: evidence for pharmacogenetics in diabetes
- 1 July 2000
- journal article
- case report
- Published by Wiley in Diabetic Medicine
- Vol. 17 (7) , 543-545
- https://doi.org/10.1046/j.1464-5491.2000.00305.x
Abstract
SUMMARY Introduction Maturity‐onset diabetes of the young (MODY) is characterized by autosomal dominantly inherited, early‐onset, non‐insulin‐dependent diabetes. Mutations in the hepatocyte nuclea...Keywords
This publication has 9 references indexed in Scilit:
- A case of hepatocyte nuclear factor-1 alpha diabetes/MODY3 masquerading as type 1 diabetes in a Mexican-American adolescent and responsive to a low dose of sulfonylurea.Diabetes Care, 1999
- Efficacy of metformin in the treatment of NIDDM. Meta-analysis.Diabetes Care, 1999
- Hyperexcitability to sulphonylurea in MODY3Diabetologia, 1998
- Maturity-onset diabetes of the young: clinical heterogeneity explained by genetic heterogeneityDiabetic Medicine, 1998
- Novel MODY3 Mutations in the Hepatocyte Nuclear Factor-1α Gene: Evidence for a Hyperexcitability of Pancreatic β-cells to Intravenous Secretagogues in a Glucose-Tolerant Carrier of a P447L MutationDiabetes, 1997
- Mutations in the Hepatocyte Nuclear Factor–1α Gene Are a Common Cause of Maturity-Onset Diabetes of the Young in the U.K.Diabetes, 1997
- Characterization of the MODY3 phenotype. Early-onset diabetes caused by an insulin secretion defect.Journal of Clinical Investigation, 1997
- Altered Insulin Secretory Responses to Glucose in Diabetic and Nondiabetic Subjects With Mutations in the Diabetes Susceptibility Gene MODY3 on Chromosome 12Diabetes, 1996
- U.K. Prospective Diabetes Study: II. Reduction in HbA1c with Basal Insulin Supplement, Sulfonylurea, or Biguanide Therapy in Maturity-onset DiabetesDiabetes, 1985